Susvimo® (ranibizumab intravitreal injection via ocular implant)

Susvimo is indicated for neovascular (wet) AMD in patients who previously responded to at least two intravitreal VEGF injections, but this policy does not recommend approval due to significant safety concerns, including a boxed warning for endophthalmitis. Coverage is limited to patients meeting the FDA indication and prior‑treatment requirement; no specific documentation requirements or effective date are provided.

"Susvimo is indicated for the treatment of patients with Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a Vascular ..."

Sign up to see full coverage criteria, indications, and limitations.